Related Experiment Video
Updated: Nov 25, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
20.6K
[How do I treat interstitial lung disease in systemic sclerosis?]
1Klinik für Rheumatologie und Klinische Immunologie, Universitätsklinik Schleswig-Holstein, Campus Lübeck, Universität zu Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland. Gabriela.Riemekasten@uksh.de.
Zeitschrift Fur Rheumatologie
|December 19, 2020
Summary
Nintedanib is the first approved medication for systemic sclerosis-associated interstitial lung disease (SSc-ILD). This overview discusses current treatment strategies and study interpretations from an experienced SSc-ILD center.
Area of Science:
- Rheumatology
- Pulmonology
- Pharmacology
Background:
- Systemic sclerosis (SSc) frequently involves interstitial lung disease (ILD).
- Several therapeutic agents have been investigated for SSc-ILD, with some demonstrating efficacy.
- Nintedanib received approval in early 2020 for SSc-ILD treatment, marking a significant advancement.
Purpose of the Study:
- To present an overview of the current therapy algorithm and strategy for SSc-ILD.
- To offer an interpretation of recent study results from an experienced SSc-ILD center.
Main Methods:
- Review of clinical trial data for SSc-ILD treatments.
- Analysis of treatment outcomes and efficacy of approved and investigational drugs.
- Expert interpretation of current therapeutic guidelines and emerging evidence.
Main Results:
- Nintedanib is the first and currently only approved drug specifically for SSc-ILD.
- Comparative studies have shown efficacy of certain treatments against placebo or control groups.
- An experienced center's perspective on managing SSc-ILD is provided.
Conclusions:
- Nintedanib represents a key therapeutic option for SSc-ILD.
- Ongoing research and expert interpretation are crucial for optimizing SSc-ILD management.
- A structured approach to therapy is essential for patients with SSc-ILD.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
552
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
552
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.9K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.9K
01:24Cystic Fibrosis: Management
317
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
317
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
288
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
288
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.3K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
327
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
327